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ABSTRACT
Protein C (PROC) deficiency is caused by mutations in the PROC gene on chromo­
some 2q14.3. Patients with PROC deficiency typically present distinguished purpura, 
intracerebral and intravascular coagulopathy, and ophthalmologic complications. 
Here, we report a rare severe form of PROC deficiency resulting from a compound 
heterozygosity in PROC. The patient was a 5­day­old female neonate born at 39 
weeks of gestation with a birth weight of 2,960 g. She was transferred to our hospital 
with running a fever at 38.5°C and with dark red patches on her feet. At admission, a 
complete blood count showed no specific findings, but levels of PROC and protein S 
were abnormally low (1% and 68%, respectively). Magnetic resonance imaging re­
vealed intracerebral hemorrhaging and parenchymal damage with dysplasia of the 
brain. Ophthalmologic examination revealed vitreous hemorrhaging with retinal 
detachment. Genetic testing revealed a missense mutation (Arg211Trp) and a frame­
shift mutation (Gly239Serfs*8) in PROC, inherited from the father and mother, res­
pectively. The patient recovered from purpura after undergoing ventriculoperi toneal 
shunting and treatment with fresh frozen plasma, warfarin sodium, and PROC con­
cen trate. This is the first report of severe neonatal PROC deficiency with purpura 
fulminans, vitreous hemorrhage, and intracerebral hemorrhage confirmed via PROC 
genetic testing, which identified a rare compound heterozygosity of PROC.
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INTRODUCTION
Congenital protein C (PROC) deficiency is a well­documented autosomal dominant 
disorder of variable penetrance. Over 150 mutations have been reported1). PROC, located 
on chromosome 2q14.3 is approximately 10,802 bp and contains 9 exons (1,790 bp), 8 of 
which encode the protein2­4).
Severe PROC deficiency (PROC activity <1 IU/dL) is a rare autosomal recessive disorder; 
its chief presentations include neonatal purpura fulminans and severe disseminated 
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intravascular coagulation (DIC) with concomitant venous 
thromboembolism5). The incidence of clinically significant 
PROC deficiency is estimated to be 1 in 20,0006). In this study, 
we describe the first genetically verified case of severe PROC 
deficiency in Korea. 
CASE REPORT
The patient was a 5­day­old female neonate, born by vaginal 
delivery at 39 weeks of gestation with a birth weight of 2,960 
g. The patient is the first child of a mother with no remarkable 
medical nor obstetric history (G1, P1, A0, D0, L1). No unusual 
events were reported during the first 3 days after birth; however, 
on the 4th day, the patient was admitted to the hospital after her 
body temperature rose to 38.5°C. On the 5th day, the skin on her 
feet turned dark red (Figure 1). When she was transferred to our 
hospital, she appeared acutely ill but her vital signs were within 
normal range (blood pressure: 78/44 mmHg, heart rate: 136 
beats per minute, respiratory rate: 55 breaths per minute, body 
temperature: 37.5°C).
Laboratory analysis revealed a white blood cell count of 
20,410/μL, hemoglobin of 12.6 g/dL, hematocrit of 36%, and 
platelet count of 219,000/μL. Liver and kidney function, C­ 
reactive protein levels, and the results for blood, urine, stool, and 
cerebrospinal fluid culture were normal. Cerebrospinal fluid 
analysis revealed a red blood cell count of 210,000/μL, white 
blood cell count of 11,730/μL, total protein of 2,271 mg/dL, and 
a glucose level of 22 mg/dL; the findings were suggestive of the 
presence of a hemorrhage. Blood coagulation tests showed a 
prothrombin time of 13.4 s (normal range: 10.0­15.3 s), activated 
partial thromboplastin time of 44.2 s (normal range: 25.4­59.8 
s), fibrinogen level of 58 mg/dL (normal range: 162­462 mg/dL), 
D­dimer level of 62.5 μg/mL (normal range: 0.0–0.5 μg/mL), 
PROC level of 1% (normal range: 50­150%), protein S level of 
68% (normal range: 80­120%), and antithrombin III level of 95% 
(normal range: 41­95%).
Neurosonography (Figure 2) and magnetic resonance imaging 
(MRI) of the patient’s brain (Figure 3) at 10 days of age revealed 
brain parenchymal destruction, intracranial hemorrhage, and 
atrophic change in the right eyeball. Examination of the fundus 
revealed posterior synechiae.
Genetic testing revealed 2 types of mutations in PROC (Figure 
4): a missense mutation (Arg211Trp) and a frameshift mutation 
(Gly239Serfs*8) causing deletion of residues 715­724. Arg211Trp 
has been associated with diseases and is often observed within 
the Korean population; however, Gly239Serfs*8 has not been 
previously reported in Koreans. Genetic testing of the parents 
revealed that the father was a carrier for Arg211Trp and the 
Figure 1. The purpura of feet at 5 days of age.
Figure 2. Neurosonogram showing symmetric hyper-echo-
genicity and extensive cystic parenchymal destruction commu-
ni cated to ventricles (arrows).
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mother was a carrier for Gly239Serfs*8. Subsequently, the patient 
was confirmed to be compound heterozygous for PROC, which 
resulted in the severe PROC deficiency. 
The patient received the following treatment. Fresh frozen 
plasma (FFP; 10 mg/kg) was administered twice a day for 28 
days: at 5 days of age, from 10 days to 27 days of age, and from 
32 days to 40 days of age. Warfarin sodium was administered at 
100 IU/kg at 30 days of age, followed by administration of 50 IU/
kg every 12 hours for the next 5 days, and finally at 0.2 mg/kg 
from 34 days of age. The level of PROC increased to 37% during 
the treatment period, but decreased to 10% after cessation of 
treatment and the patient was considered to be recovered from 
Figure 3. Brain magnetic resonance imaging (MRI) shows: subacute extensive 
hemorrhages in the bilateral periventricular and subcortical white matter; parenchy-
mal destruction with leukomalatic changes; communication with lateral ventricles; 
atrophic change of the right eyeball (arrow), with septated fluid collection and 
hemorrhage in the right vitreous cavity.
Figure 4. Genetic testing of the patient found a missense mutation (Arg211Trp) of the 
protein C gene, and a frameshift mutation (Gly239Serfs*8).  
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Management of severe PROC deficiency includes an acute 
phase of replacement therapy with FFP or PROC concentrate, 
and an anticoagulant with warfarin or low­molecular­weight 
heparin as maintenance therapy16­18). The treatment reported 
here includes administration of FFP 4­5 times per week for 1 
month, PROC concentrate, and oral enoxaparin after discharge.
Twenty cases of homozygous PROC deficiency presenting 
neonatal purpura fulminans have been reported worldwide 
since 1998. Most of these cases had a poor clinical outcome, 
including complete blindness (75%), severe neurological im­
pairment (33%), or death within the first few days after birth 
(10%)19). Other major morbidities, such as renal failure, epilepsy, 
and impaired growth and development, have also been reported. 
Only 3 patients have been reported to not exhibit any major 
morbidity because of early onset of treatment and continuous 
therapy with PROC concentrate19,20).
Overall, the present study describes a case of severe PROC 
deficiency in a neonate that presented purpura fulminans, 
vitreous hemorrhage, and intracerebral hemorrhage. The 
diagnosis was confirmed by identification of a rare compound 
heterozygosity in PROC.
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